Spero Therapeutics, Inc. (Nasdaq: SPRO) is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases. The company's lead asset is tebipenem pivoxil hydrobromide (tebipenem HBr), branded as Utebzi, which was developed in collaboration with GSK. Utebzi is the first and only oral carbapenem antibiotic approved in the United States, indicated for adult patients with complicated urinary tract infections (cUTIs), including pyelonephritis, who have limited or no alternative oral treatment options. Spero's business model relies heavily on strategic partnerships, notably its licensing agreement with GSK, which covers development and commercialization rights in the U.S. and most international territories (excluding select Asian markets). Spero also receives federal funding support from BARDA.

Research as of 19 Jun 2026